SCHEMBL376731

SCHEMBL376731

CC1(C)CCN(c2ccc(C(=N)NS(=O)(=O)c3ccc(F)c([N+](=O)[O-])c3)cc2)CC1

nearest known ligand 0.52

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
BCL2L1 Q07817 11/20 0.52
BCL2 P10415 10/20 0.52
ALB P02768 1/20 0.47
BCL2L2 Q92843 1/20 0.47
LMNA P02545 5/20 0.43
ALDH1A1 P00352 4/20 0.43
MAPT P10636 5/20 0.42
MEN1 O00255 3/20 0.42
MAPK1 P28482 3/20 0.42
KMT2A Q03164 3/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
HTT P42858 2/20 0.41
MITF O75030 1/20 0.41
GAA P10253 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.40
VCAM1 P19320 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3589187 0.84 BCL2L1 (0.50) BCL2L1BCL2
SCHEMBL376471 0.83 BCL2L1 (0.55) BCL2L1BCL2
SCHEMBL376747 0.83 BCL2L1 (0.58) BCL2L1BCL2
SCHEMBL376937 0.82 BCL2L1 (0.55) BCL2L1BCL2
SCHEMBL387620 0.81 BCL2L1 (0.56) BCL2L1BCL2
SCHEMBL376732 0.81 BCL2 (0.44) BCL2L1BCL2ALBBCL2L2LMNA
SCHEMBL13503899 0.81 BCL2 (0.44) BCL2L1BCL2ALBBCL2L2LMNA
SCHEMBL376415 0.80 BCL2L1 (0.52) BCL2L1BCL2LMNAALDH1A1MAPT
SCHEMBL376729 0.80 BCL2L1 (0.58) BCL2L1BCL2
SCHEMBL376908 0.79 BCL2L1 (0.84) BCL2L1BCL2ALBBCL2L2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1765778-B1 N-SULFONYLCARBOXIMIDAMIDE APOPTOSIS PROMOTERS ABBOTT LAB (US) 2012-01-25 EP disclosed
US-20100035879-A1 N-SULFONYLCARBOXIMIDAMIDE APOPTOSIS PROMOTERS ABBOTT LABORATORIES 2010-02-11 US disclosed
US-7585858-B2 N-sulfonylcarboximidamide apoptosis promoters ABBOTT LABORATORIES (US) 2009-09-08 US disclosed
US-20050272744-A1 N-sulfonylcarboximidamide apoptosis promoters ABBVIE INC. 2005-12-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100035879-A1 N-SULFONYLCARBOXIMIDAMIDE APOPTOSIS PROMOTERS BAX, BCL2, BAD BCL2L1 18/4885BCL2 2/4885ALB 4841/4885
US-20050272744-A1 N-sulfonylcarboximidamide apoptosis promoters BAX, BCL2, BAD BCL2L1 18/4885BCL2 2/4885ALB 4841/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.